Genmab — Juli 2017
-
4 Things That Matter When Johnson & Johnson Reports Its Second-Quarter Results | The Motley Fool
Headline figures aside, this is what investors should really be paying attention to when J&J reports on Tuesday, July 18.
The Motley Fool (www.fool.com)
-
"For those of you who follow J&J pretty closely, you may have also noticed that the company increased its dividend this year by "just" 5%, which is its smallest percentage increase this decade. My instincts tell me that it likely did this to retain as much of its operating cash as possible to fund future acquisitions, many of which I expect to be in pharmaceuticals." Til når dara virker udenfor MM..
-
God morgen.
-
-
Jeg går lidt og frygter at produktionslinien har svært ved at følge med den stigningstakt af salg .. og det derved ryger i restordre, det ville jo give lave tal for salg og så får vi en lussing , ikke pga af dårlig virkning men simplehen fordi produktionslinien ikke kan følge med ... er der nogen der har indsigt i produktionslinien???? jeg frygter skuffende tal da forventninger er høje.
-
-
...Også Genmab, der mandag steg 0,3 pct. til 1434 kr., har fået nyt fra Schweiz. Novartis, der har salgsrettighederne til Genmabs kræftmiddel Arzerra, tjente flere penge end ventet i sit andet kvartal. Det skete til trods for et lille fald i omsætningen.
-
@Joakim von And vedr. prod.linje. Vil du ikke stille spørgsmålet på Q&A i august? Jeg vil rigtig gerne høre Genmabs kommentar.
Og god morgen alle sammen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind